Xbrane Biopharma AB · OMXSTO:XBRANE
Xbrane Biopharma AB — Q2 2022 Earnings Presentation
12 slides from Xbrane Biopharma AB's earnings presentation, Jul 22, 2022
Slide 1: Xbrane Biopharma AB Presentation Interim Report January – June 2022
Xbrane Biopharma AB Presentation Interim Report January – June 2022 “Production for the launch of XlucaneTM in Europe Q1 2023, is being initiated*” Martin Åmark, CEO Solna July 22 nd, 2022 *Post expiry of originator patents SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Interim Report January
Slide 2: Disclaimer
Disclaimer You must read the following before continuing. The following applies to this document and the information provided in Company may alter. modify or otherwise change in any manner the content of this presentation. without obligation to this presentation by Xbrane Biopharma AB (publ) (the “C
Slide 3: Xbrane has a portfolio addressing €53 billion of peak reference product sales
Xbrane has a portfolio addressing €53 billion of peak reference product sales Peak Reference Patent Development Commercialization Candidate Indication sales Next milestone Product Expiry Phase Partner estimate* H2 2022 : EU • Age-related macular approval degeneration H2 2022: Submission 2020/22 Xluc
Slide 4: Xlucane updated timeline to launch
XlucaneTM updated timeline to launch 2021 2022 2023 Regulatory process EU Sep: Sep: Nov: Submission CHMP Approval opinion Production launch volume July: Q1: EU patent EU launch expiry Regulatory process US (Standard timeline from submission: 12 month) H2: Submission SCIENCE FOR HIGH QUALITY BIOSIMIL
Slide 5: Xlucane – prospects of launch in Europe
XlucaneTM – prospects of launch in Europe XlucaneTM is addressing a €5.1 billion market +35% volume market share achieved at month 12 in opportunity in Europe recent biosimilar launches in Europe • Retinal VEGF inhibitor market in Europe generated sales of € 5.1 billion in 2021 – Lucentis® sales of
Slide 6: Ambition to be the most attractive employer within our field
Ambition to be the most attractive employer within our field Certified as a Great Place to Work® Equality Managment team No of employees +30% YoY 80 * 70 70 64 60 58 54 54 Women Men Women Men 50 Experience 40 50 International 45 30 40 20 35 10 30 25 0 Q2 '21 Q3 '21 Q4 '21 Q1 22 Q2 22 Foreign Sweden
Slide 7: Upcoming Capital Market Events 2022
Upcoming Capital Market Events 2022 13th Annual Healthcare Xbrane Capital Market Day Conference August 2022 September 2022 (invitations within short) SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Interim Report January – March 2022
Slide 8: Interim Report January – June 2022, Financials
Interim Report January – June 2022, Financials SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Interim Report January – March 2022
Slide 9: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 0 Total Company Expenses in the quarter was in line with -8,6 -8,8 -6 -7,9 -6,1 last year even if the R&D costs increased somewhat -10 and the overall G&A costs showed a decline. -20 -28,9 The expensed R&D costs for the quarter amount
Slide 10: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Comparing “like-for-like” year-on-year, the total Operating Costs 0 have increased with 10,2% -8,6 -8,8 -6 -7,9 -6,1 -10 The total R&D costs (incl. Intangible Asset of SEK 5.7m) amount to -20 -28,9 SEK 58.6m, 90.6% of the total costs
Slide 11: Cash and Cash Equivalents Shareholders’ Equity
Cash and Cash Equivalents Shareholders’ Equity 450 500 462,4 400 383,4 450 431,7 396,3 350 400 365,7 295,2 301,5 350 300 250,1 300 250 249,7 250 200 200 150 129,3 150 100 100 50 50 0 0 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 At the end of the second quarter 2022, Cash a
Slide 12: Q&A
Q&A SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Interim Report January – March 2022